Physician profile

Ryan Cochrane

Psychiatric/Mental Health (Nurse Practitioner) · Salt Lake City, UT

NPI 1285164236

$2,055.94

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$589.48

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $1,042.76 2021-2023
Alkermes, INC. $415.93 2021-2022
Idorsia Pharmaceuticals US INC $217.47 2023 Quviviq
Janssen Pharmaceuticals, INC $167.39 2021-2022
Otsuka America Pharmaceutical, INC. $128.06 2021-2022
Indivior INC. $45.26 2022-2023 Sublocade
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $27.23 2021
Axsome Therapeutics, INC. $11.84 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ryan Cochrane

$2,055.94

in general payments reported 2019-2025

Years
2021-2023
Top company
Abbvie INC.

https://glasscript.com/doctor/10469695/ryan-cochrane

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.